Baird Financial Group, Inc. Esperion Therapeutics, Inc. Transaction History

Baird Financial Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$31.18 - $52.71 $662,699 - $1.12 Million	-21,254 Closed	0 $0
Q2 2020 Oct 22, 2020	BUY	$30.04 - $51.31 $99,192 - $169,425	3,302 Added 18.39%	21,254 $1.09 Million
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $539,278 - $921,117	17,952 New	17,952 $1.07 Million
Q1 2020 May 14, 2020	SELL	$27.44 - $73.84 $516,667 - $1.39 Million	-18,829 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $10,797 - $18,245	305 Added 1.65%	18,829 $1.12 Million
Q3 2019 Nov 14, 2019	BUY	$34.47 - $47.53 $29,265 - $40,352	849 Added 4.8%	18,524 $679,000
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $708,767 - $924,932	17,675 New	17,675 $823,000

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $171M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Baird Financial Group, Inc. with notifications on news.